News
Two molecules offer great potential to combat cancer and chronic infections
To fight viral infections, your immune system calls on CD8 T cells to kill the infected cells. The CD8 T cells can also be used in immunotherapy...
New guidelines help ensure optimal outcomes for children treated with CAR-T Cell Therapy
While chimeric antigen receptor (CAR)-T cell therapy has demonstrated positive response rates in children with relapsed and/or refractory...
Could athersys play a role in the progression of CAR-T Therapy?
One of newest and most exciting approved treatments for cancer is the use of CAR-T therapy. CAR stands for chimeric antigen receptor and T stands...
Advances in T cell therapy may fight cancer without side effects
The human immune system is truly a wonder. It plays a critical role in our body’s defense to invading disease. Like a home security system, it is on...
AI enables personalized treatment for myeloma
A multidisciplinary team of researchers has developed an artificial intelligence platform that could enable doctors to prescribe personalized...
Early Signs of Efficacy Seen With Mesothelin CAR T-Cell Therapy
Mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy has shown early evidence of efficacy in a phase I trial of patients with...
Minimal residual disease analysis in myeloma – when, why and where
The primary hurdle in the path to curing multiple myeloma (MM) is defining a validated minimal residual disease (MRD) and its utility in the...
Many questions to ask in setting national coverage for CAR-T Therapies
Next week, a CMS committee will hold a daylong meeting to discuss a national coverage determination (NCD) for chimeric antigen receptor (CAR) T-cell...
Scientists race to improve ‘living drugs’ to fight cancer
Aaron Reid is lying in a hospital bed at the National Institutes of Health Clinical Center when doctors arrive to make sure he's ready for his...
Dr. Munshi on latest treatment developments in multiple myeloma
US FDA approves first non-gene edited allogeneic CAR T-cell candidate for trials
Unlike gene-edited CAR T-cell therapies, this approach does not cut the genome to knock out, or knock in, a gene, says Celyad. Read more:...
Lenalidomide-based maintenance therapy may be the most effective in myeloma
Continuous therapy with lenalidomide may lead to the greatest improvements in survival outcomes among patients with newly diagnosed multiple myeloma...